2024 CPT® Errata and Technical Corrections | AMA

Pathology and Laboratory Genomic Sequencing Procedures and Other Molecular Multianalyte Assays

Testing for somatic alterations in neoplasms may be reported differently depending on whether combined or separate methods and analyses are used for both DNA and RNA analytes. Procedures for somatic alterations in neoplasms which include DNA analysis or DNA and RNA analysis using a single combined method are reported with 81445, 81450, 81455, 81457, 81458, 81459, 81462, 81463, 81464. RNA analysis performed using a separate method is reported with 81449, 81451, 81456. When evaluation for tumor mutation burden (TMB) and/or microsatellite instability (MSI) is performed as part of the same test for somatic alterations in neoplasms, report 81457, 81458, 81459. When a genomic sequencing procedure (GSP) is performed on cell-free nucleic acid (eg, plasma), sometimes referred to as a liquid biopsy, report 81462, 81463, 81464.

Revise guideline by adding code 81457 to the Pathology and Laboratory Genomic Sequencing Procedures and Other Molecular Multianalyte Assays subsection.

Source: https://www.ama-assn.org/system/files/2024-cpt-corrections-errata.pdf